TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Bam, Rujuta A ^a   Hansen, Derek ^a   Irrinki, Alivelu ^a   Mulato, Andrew ^a   Jones, Gregg S ^a   Hesselgesser, Joseph ^a   Frey, Christian R ^a   Cihlar, Tomas ^a   Yant, Stephen R ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Antiviral agents; GS 9620; Human immunodeficiency virus; Interferons; TLR7

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GARDIQUIMOD; IMIQUIMOD; INTERFERON; INTERFERON ANTIBODY; INTERLEUKIN 6; RECOMBINANT ALPHA INTERFERON; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; VESATOLIMOD; ANTIBODY; ANTIVIRUS AGENT; GS-9620; PTERIDINE DERIVATIVE;

ACUTE DISEASE; ANTIRETROVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; EC50; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; LIMIT OF QUANTITATION; LONG TERMINAL REPEAT; MACROPHAGE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; PRIORITY JOURNAL; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CD8+ T LYMPHOCYTE; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MONONUCLEAR CELL; PATHOGENICITY; VIROLOGY;

ANTIBODIES; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; INTERFERONS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; PTERIDINES; TOLL-LIKE RECEPTOR 7; VIRUS REPLICATION;

EID: 85009288370     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01369-16     Document Type: Article

References (39)

1. Gordon S. 2002. Pattern recognition receptors: doubling up for the innate immune response. Cell 111:1-14. https://doi.org/10.1016/S0092-8674(02)01201-1.
2. Mifsud EJ, Tan ACL, Jackson DC. 2014. TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease. Front Immunol 5:79. https://doi.org/10.3389/fimmu.2014.00079.
3. Kaisho T, Akira S. 2002. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589:1-13. https://doi.org/10.1016/S0167-4889(01)00182-3.
4. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. 2001. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 17: 194:863-869. https://doi.org/10.1084/jem.194.6.863.
5. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G. 2002. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to Cp G oligodeoxynucleotides. J Immunol 168: 4531-4537. https://doi.org/10.4049/jimmunol.168.9.4531.
6. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, Puel A, Biswas SK, Moshous D, Picard C, Jais JP, D'Cruz D, Casanova JL, Trouillet C, Geissmann F. 2010. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33: 375-386. https://doi.org/10.1016/j.immuni.2010.08.012.
7. Douagi I, Gujer C, Sundling C, Adams WC, Smed-Sorensen A, Seder RA, Karlsson Hedestam GB, Lore K. 2009. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacy-toid dendritic cells. J Immunol 182:1991-2001. https://doi.org/10.4049/jimmunol.0802257.
8. + T-cells in patients chronically infected with hepatitis C virus. Cell Immunol 264:150-155. https://doi.org/10.1016/j.cellimm.2010.06.001.
9. Caramalho Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. 2003. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med 197:403-411. https://doi.org/10.1084/jem.20021633.
10. + T cells. J Immunol 175:1551-1557. https://doi.org/10.4049/jimmunol.175.3.1551.
11. + cells after Toll-like receptor 7/8 signalling. PLoS One 3:e1999. https://doi.org/10.1371/journal.pone.0001999.
12. Song Y, Zhuang Y, Zhai S, Huang D, Zhang Y, Kang W, Li X, Liu Q, Yu Q, Sun Y. 2009. Increased expression of TLR7 in CD8(+) T cells leads to TLR7-mediated activation and accessory cell-dependent IFNgamma production in HIV type 1 infection. 2009. AIDS Res Hum Retroviruses 25:1287-1295. https://doi.org/10.1089/aid.2008.0303.
13. García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 70:1032-1060. https://doi.org/10.1128/MMBR.00027-06.
14. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu Rev Immunol 21:335-376. https://doi.org/10.1146/annurev.immunol.21.120601.141126.
15. Buitendijk M, Eszterhas SK, Howell AL. 2013. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses 29:907-918. https://doi.org/10.1089/aid.2012.0313.
16. Schlaepfer E, Audigé A, Joller H, Speck RF. 2006. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 176: 2888-2895. https://doi.org/10.4049/jimmunol.176.5.2888.
17. Fosdick A, Zheng J, Pflanz S, Frey CR, Hesselgesser J, Halcomb RL, Wolfgang G, Tumas DB. 2014. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel TLR7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther 348:96-105. https://doi.org/10.1124/jpet.113.207878.
18. Roethle PA, Mc Fadden RM, Yang H, Hrvatin P, Hui H, Graupe M, Gallagher B, Chao J, Hesselgesser J, Duatschek P, Zheng J, Lu B, Tumas DB, Perry J, Halcomb RL. 2013. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis. J Med Chem 56:7324-7333. https://doi.org/10.1021/jm400815m.
19. Sloan DD, Irrinki A, Tsai A, Kaur J, Lalezari J, Murry J, Cihlar T. 2015. TLR7 agonist GS-9620 activates HIV-1 in PBMCs from HIV-infected patients on cART, abstr 417. Abstr 22nd Annu Conf Retrovir Opportunist Infect, Seattle, WA.
20. Whitney JB, Lim S, Osuna CE, Sanisetty S, Barnes TL, Hraber P, Cihlar T, Geleziunas R, Hesselgesser J. 2015. Treatment with a TLR7 agonist induces transient viremia in SIV-infected ART-suppressed monkeys, abstr 108. Abstr 22nd Annu Conf Retrovir Opportunist Infect, Seattle, WA.
21. Whitney JB, Lim S, Osuna CE, Sanisetty S, Barnes TL, Cihlar T, Miller M, Geleziunas R, Hesselgesser J. 2016. Repeated TLR7 agonist treatment of SIV+ monkeys on ART can lead to viral remission, abstr 95LB. Abstr 23rd Annu Conf Retrovir Opportunist Infect, Boston, MA.
22. Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, Massetto B, Ye Z, Pflanz S, Garrison KL, Gaggar A, Mani Subramanian G, Mc Hutchison JG, Kottilil S, Freilich B, Coffin CS, Cheng W, Kim YJ. 2015. The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol 63:320-328. https://doi.org/10.1016/j.jhep.2015.02.037.
23. Cavrois M, De Noronha C, Greene WC. 2002. A sensitive and specific enzyme based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20:1151-1154. https://doi.org/10.1038/nbt745.
24. Goujon C, Malim MH. 2010. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macro-phages and T cells. J Virol 84:9254-9266. https://doi.org/10.1128/JVI.00854-10.
25. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:552-559. https://doi.org/10.1038/nm1589.
26. Gurney KB, Colantonio AD, Blom B, Spits H, Uittenbogaart CH. 2004. Endogenous\FNa production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J Immunol 173:7269-7276. https://doi.org/10.4049/jimmunol.173.12.7269.
27. Bogdan C. 2000. The function of type I interferons in antimicrobial immunity. Curr Opin Immunol 12:419-424. https://doi.org/10.1016/S0952-7915(00)00111-4.
28. Dominguez-Villar M, Gautron AS, de Marcken M, Keller MJ, Hafler DA. 2015. TLR7 induces anergy in human CD4(+) T cells. Nat Immunol 16:118-128. https://doi.org/10.1038/ni.3036.
29. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, Dieffenbach CW, Friedman RM, Meltzer MS. 1990. Regulation of HIV replication in infected monocytes by IFNalpha. Mechanisms for viral restriction. J Immunol 145:2669-2676.
30. Meylan PR, Guatelli JC, Munis JR, Richman DD, Kornbluth RS. 1993. Mechanisms for the inhibition of HIV replication by interferons-alpha,-beta, and-gamma in primary human macrophages. Virology 193: 138-148. https://doi.org/10.1006/viro.1993.1110.
31. Shirazi Y, Pitha PM. 1992. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol 66: 1321-1328.
32. Cheney KM, Mc Knight A. 2010. Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication. PLoS One 5:e13521. https://doi.org/10.1371/journal.pone.0013521.
33. + T cells indirectly via TNF-a. J Immunol 186:4314-4324. https://doi.org/10.4049/jimmunol.1003174.
34. Yee JK, Friedmann T, Burns JC. 1994. Generation of high-titer pseu-dotyped retroviral vectors with very broad host range. Methods Cell Biol 43(Pt A):99-112.
35. Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, Tsai A, Niedziela-Majka A, Stray KM, Sakowicz R, Cihlar T. 2013. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One 8:e74163. https://doi.org/10.1371/journal.pone.0074163.
36. Butler SL, Hansen MS, Bushman FD. 2001. A quantitative assay for HIV DNA integration in vivo. Nat Med 7:631-634. https://doi.org/10.1038/87979.
37. Julias JG, Ferris AL, Boyer PL, Hughes SH. 2001. Replication of phe-notypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse trans-criptase. J Virol 75:6537-6546. https://doi.org/10.1128/JVI.75.14.6537-6546.2001.
38. Mbisa JL, Delviks-Frankenberry KA, Thomas JA, Gorelick RJ, Pathak VK. 2009. Real-time PCR analysis of HIV-1 replication post-entry events. Methods Mol Biol 485:55-72. https://doi.org/10.1007/978-1-59745-170-3-5.
39. Quan Y, Rong L, Liang C, Wainberg MA. 1999. Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. J Virol 73:6700-6707.